Authors: Marta Scorsetti Piera Navarria Fiorenza De Rose AnnaMaria Ascolese Elena Clerici Ciro Franzese Francesca Lobefalo Giacomo Reggiori Pietro Mancosu Stefano Tomatis Antonella Fogliata Luca Cozzi
Publish Date: 2014/06/17
Volume: 140, Issue: 11, Pages: 1937-1945
Abstract
Seventyfive consecutive patients all stages IIIA and IIIB were treated with RA Among them 71 were men 254 presented unspecified nonsmall cell lung cancer 413 adenocarcinoma and 333 squamous cell carcinoma Of them 547 received sequential chemotherapy while 453 were treated with concomitant regimen Dose prescription ranged from 54 to 72 Gy Analysis included survival local control LC and toxicity profilesMedian followup was 212 months range 6–75 One two and fiveyear actuarial LC was 919 ± 32 795 ± 57 and 674 ± 95 respectively Median survival was 190 ± 11 months Actuarial survival at 1–2–5 years was 800 ± 46 385 ± 59 and 152 ± 49 respectively Acute toxicity of G2 was reported in 24 253 and 40 of patients for lung esophageal and hematological profiles A total of 27 of patients reported G3 toxicity in the esophagus and 53 of the patients experienced G3–G4 hematological toxicity Significant differences were observed in all cases between concomitant and sequential chemotherapy regiments Only 13 1 patient showed G2 lung late toxicity No significant correlation was found between toxicity and organ’s irradiation levels
Keywords: